When was ReGENE founded?

ReGENE was founded in 2024 and raised its 1st funding round within a year of its incorporation.

Where is ReGENE located?

ReGENE is headquartered in Springfield, United States.

Is ReGENE a funded company?

ReGENE is a funded company, having raised a total of $***** in its 1st and only funding round, a Grant (prize money) round on Feb 01, 2024.

When was the latest funding round of ReGENE?

ReGENE's latest funding was a $***** Grant (prize money) round on Feb 01, 2024, with participation from 1 investor. Its primary sector is Diversified Pharmaceuticals. In United States, the Diversified Pharmaceuticals sector has seen $585M in funding in 2026 to date.

Where does ReGENE rank among its competitors?

ReGENE ranks 1795th amongst 1820 active competitors, of which 96 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of ReGENE?

ReGENE's top competitors include AbbVie, Amgen and Gilead. Among them, AstraZeneca secured the most recent funding round in July, 2025.

ReGENE - 2026 Company Profile, Team, Funding & Competitors

ReGENE is a funded company based in Springfield (United States), founded in 2024 by Alexander Suvorov. It operates as a Developer of therapies to prevent and treat aging-associated non-communicable diseases. ReGENE has raised an undisclosed amount in funding. The company has 1820 active competitors, including 96 funded and 199 that have exited. Its top competitors include companies like AbbVie, Amgen and Gilead.

Company Details

Developer of therapies to prevent and treat aging-associated non-communicable diseases. The company focuses on developing treatments addressing the underlying mechanisms of aging. It uses evolutionary biology insights to identify factors contributing to the aging process. The goal is to enhance the quality of life during aging.

Key Metrics

Founded Year

2024

Location

Springfield, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Feb 01, 2024, $*****

Investors

HHS

Ranked

1795^th among 1820 active competitors

Similar Companies

AbbVie & 1847 more

View ReGENE's full profile

ReGENE has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Feb 01, 2024 for $*****. 1 investor participated in its latest round. ReGENE has 1 institutional investor.

Here is the list of recent funding rounds of ReGENE:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 01, 2024	6595202	Grant (prize money)	8469940	6806971	2933941	9456760

Access funding benchmarks and valuations. Sign up today!

View details of ReGENE's funding rounds and investors

The founders of ReGENE is Alexander Suvorov.

Here are the details of ReGENE's key team members:

Alexander Suvorov: Co-Founder of ReGENE.

View details of ReGENE's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ReGENE include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of ReGENE, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 9 others	81/100
2nd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	81/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	Jindal ventures, Seaside Private Capital ... & 17 others	80/100
4th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
5th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
6th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	73/100
7th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
8th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	70/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, Triodos Investment Management ... & 11 others	70/100
10th	Genentech 1976, San Francisco (United States), Acquired	R&D company focused on manufacturing drugs for multiple therapeutic areas	$72.5M	Ignite 500, The Column Group & 4 others	69/100
1795th	ReGENE 2024, Springfield (United States), Funding Raised	Developer of therapies to prevent and treat aging-associated non-communicable diseases	-	HHS	15/100